-By ArdorComm News Network
May 3, 2025
Researchers at Sant Pau Research Institute, in partnership with Sant Pau Hospital and the Josep Carreras Leukaemia Research Institute, have developed a groundbreaking CAR-T cell therapy—HSP-CAR30—targeting the CD30 protein. This therapy has shown promising results in a Phase I clinical trial for patients with refractory CD30+ lymphomas, including Hodgkin lymphoma.
Key Highlights:
- 100% overall response rate in 10 patients with relapsed or treatment-resistant CD30+ lymphoma.
- 50% achieved complete remission, with no signs of cancer on scans and tests.
- 60% of complete responders remained cancer-free after 34 months.
- No serious side effects were observed—only mild, manageable symptoms like low-grade cytokine release syndrome and no neurotoxicity.
What Makes HSP-CAR30 Unique?
Traditional CAR-T therapies for CD30+ lymphoma have struggled with limited cell persistence and high relapse rates. The HSP-CAR30 version is optimized to:
- Target a stable region of the CD30 protein, reducing immune evasion by tumor cells.
- Promote long-lasting immune memory by enhancing central memory (TCM) and stem-like memory T cells (TSCM-LIKE).
- Use a new manufacturing mix of IL-21, IL-7, and IL-15 to boost durable T-cell responses.
Phase II Trial Update:
- 32 patients have now been treated in the ongoing Phase II trial.
- Over 55% have achieved complete remission.
- Data from both trials were presented at the 2024 ASH Annual Meeting.
A Step Forward in Europe:
This marks Europe’s first successful CAR-T30 study, potentially offering new hope to patients with limited treatment options.
Backed by Strong Support:
The project received funding and resources from:
- Josep Carreras Leukaemia Foundation
- La Marató de TV3
- Carlos III Health Institute
- ‘La Caixa’ Foundation
- European Union and NextGen EU
- Blood and Tissue Bank, among others.
With further study, HSP-CAR30 could redefine treatment for CD30+ lymphomas and bring renewed hope to patients who have exhausted standard options.
Source: ANI